Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer
Phase 2 Study of Pralatrexate in Female Patients With Previously-treated Advanced or Metastatic Breast Cancer
Status: Archived
The West Clinic, PC
mi
from
Memphis, TN
Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer
Phase 2 Study of Pralatrexate in Female Patients With Previously-treated Advanced or Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
The West Clinic, PC
mi
from
Memphis, TN
A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax
A Phase 1 Study to Assess the Effect of a CYP3A Inducer (Rifampin) on the Pharmacokinetics of Navitoclax
Status: Archived
Clinical Research Facility
mi
from
Santa Monica, CA
A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax
A Phase 1 Study to Assess the Effect of a CYP3A Inducer (Rifampin) on the Pharmacokinetics of Navitoclax
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Santa Monica, CA
Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatments
Pilot Study of CS-1008 in Combination With FOLFIRI (Irinotecan, Leucovorin, and 5-fluorouracil [5-FU]) in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Failed First-line Treatment That Was Not Irinotecan-based.
Status: Archived
Mayo Clinic Phoenix
mi
from
Phoenix, AZ
Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatments
Pilot Study of CS-1008 in Combination With FOLFIRI (Irinotecan, Leucovorin, and 5-fluorouracil [5-FU]) in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Failed First-line Treatment That Was Not Irinotecan-based.
Status: Archived
Updated: 1/1/1970
Mayo Clinic Phoenix
mi
from
Phoenix, AZ
Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatments
Pilot Study of CS-1008 in Combination With FOLFIRI (Irinotecan, Leucovorin, and 5-fluorouracil [5-FU]) in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Failed First-line Treatment That Was Not Irinotecan-based.
Status: Archived
Mayo Clinic - Division of Nephrology
mi
from
Rochester, MN
Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatments
Pilot Study of CS-1008 in Combination With FOLFIRI (Irinotecan, Leucovorin, and 5-fluorouracil [5-FU]) in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Failed First-line Treatment That Was Not Irinotecan-based.
Status: Archived
Updated: 1/1/1970
Mayo Clinic - Division of Nephrology
mi
from
Rochester, MN
Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatments
Pilot Study of CS-1008 in Combination With FOLFIRI (Irinotecan, Leucovorin, and 5-fluorouracil [5-FU]) in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Failed First-line Treatment That Was Not Irinotecan-based.
Status: Archived
Mayo Clinic Rochester
mi
from
Rochester, MN
Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatments
Pilot Study of CS-1008 in Combination With FOLFIRI (Irinotecan, Leucovorin, and 5-fluorouracil [5-FU]) in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Failed First-line Treatment That Was Not Irinotecan-based.
Status: Archived
Updated: 1/1/1970
Mayo Clinic Rochester
mi
from
Rochester, MN
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
A Phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Archived
Loma Linda Oncology Medical Group
mi
from
Merced, CA
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
A Phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Archived
Updated: 1/1/1970
Loma Linda Oncology Medical Group
mi
from
Merced, CA
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
A Phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Archived
Virginia Piper Cancer Institute
mi
from
Minneapolis, MN
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
A Phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Archived
Updated: 1/1/1970
Virginia Piper Cancer Institute
mi
from
Minneapolis, MN
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
A Phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Archived
The Cancer Institute of New Jersey (CINJ)
mi
from
New Brunswick, NJ
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
A Phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Archived
Updated: 1/1/1970
The Cancer Institute of New Jersey (CINJ)
mi
from
New Brunswick, NJ
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
A Phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Archived
New Mexico Cancer Care Alliance
mi
from
Albuquerque, NM
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
A Phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Archived
Updated: 1/1/1970
New Mexico Cancer Care Alliance
mi
from
Albuquerque, NM
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
A Phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Archived
Arena Oncology Associates
mi
from
New Hyde Park, NY
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
A Phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Archived
Updated: 1/1/1970
Arena Oncology Associates
mi
from
New Hyde Park, NY
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
A Phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Archived
Bend Memorial Clinic
mi
from
Bend, OR
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
A Phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Archived
Updated: 1/1/1970
Bend Memorial Clinic
mi
from
Bend, OR
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
A Phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Archived
Cancer Centers of the Carolinas - Faris Road
mi
from
Greenville, SC
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
A Phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Archived
Updated: 1/1/1970
Cancer Centers of the Carolinas - Faris Road
mi
from
Greenville, SC
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
A Phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Archived
South Texas Oncology and Hematology
mi
from
San Antonio, TX
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
A Phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Archived
Updated: 1/1/1970
South Texas Oncology and Hematology
mi
from
San Antonio, TX
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Birmingham Hematology and Oncology Associates, LLC
mi
from
Birmingham, AL
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Birmingham Hematology and Oncology Associates, LLC
mi
from
Birmingham, AL
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Highlands Oncology Group
mi
from
Springdale, AR
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Highlands Oncology Group
mi
from
Springdale, AR
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Clopton Clinic Hematology/Oncology
mi
from
Jonesboro, AR
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Clopton Clinic Hematology/Oncology
mi
from
Jonesboro, AR
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Hematology Oncology Services of Arkansas
mi
from
Little Rock, AR
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Hematology Oncology Services of Arkansas
mi
from
Little Rock, AR
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Compassionate Cancer Care Medical Group, Inc.
mi
from
Corona, CA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Compassionate Cancer Care Medical Group, Inc.
mi
from
Corona, CA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Wilshire Oncology Medical Group, Inc.
mi
from
Pomona, CA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Wilshire Oncology Medical Group, Inc.
mi
from
Pomona, CA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Loma Linda Medical Center
mi
from
Loma Linda, CA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Loma Linda Medical Center
mi
from
Loma Linda, CA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Comprehensive Cancer Center
mi
from
Palm Springs, CA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Comprehensive Cancer Center
mi
from
Palm Springs, CA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Sutter Health Cancer Research Group
mi
from
Greenbrae, CA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Sutter Health Cancer Research Group
mi
from
Greenbrae, CA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Doctors Medical Center, Cancer Center
mi
from
San Pablo, CA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Doctors Medical Center, Cancer Center
mi
from
San Pablo, CA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Florida Cancer Specialist
mi
from
Fort Myers, FL
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Florida Cancer Specialist
mi
from
Fort Myers, FL
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Cancer Care of North Florida, P.A.
mi
from
Lake City, FL
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Cancer Care of North Florida, P.A.
mi
from
Lake City, FL
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Lakeland Regional Cancer Care Center - St. Joseph
mi
from
St. Joseph, MI
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Lakeland Regional Cancer Care Center - St. Joseph
mi
from
St. Joseph, MI
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Hematology Oncology Associates
mi
from
Lake Worth, FL
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Hematology Oncology Associates
mi
from
Lake Worth, FL
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Pasco Hernando Oncology Associates P.A
mi
from
Brooksville, FL
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Pasco Hernando Oncology Associates P.A
mi
from
Brooksville, FL
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Space Coast Cancer Center
mi
from
Titusville, FL
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Space Coast Cancer Center
mi
from
Titusville, FL
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Straub Clinic And Hospital
mi
from
Honolulu, HI
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Straub Clinic And Hospital
mi
from
Honolulu, HI
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Kaiser Foundation Hospital-San Diego
mi
from
San Diego, CA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Kaiser Foundation Hospital-San Diego
mi
from
San Diego, CA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Kootenai Cancer Center
mi
from
Coeur d'Alene, ID
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Kootenai Cancer Center
mi
from
Coeur d'Alene, ID
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Oncology Specialist, SC
mi
from
Park Ridge, IL
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Oncology Specialist, SC
mi
from
Park Ridge, IL
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Cancer Center of Kansas
mi
from
Wichita, KA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Cancer Center of Kansas
mi
from
Wichita, KA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Peninsula Regional Medical Center
mi
from
Salisbury, MD
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Peninsula Regional Medical Center
mi
from
Salisbury, MD
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Saints Medical Center
mi
from
Lowell, MA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Saints Medical Center
mi
from
Lowell, MA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Haematology-Oncology Associates of Ohio and Michigan, PC
mi
from
Lambertville, MI
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Haematology-Oncology Associates of Ohio and Michigan, PC
mi
from
Lambertville, MI
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
St. John's Pediatrics
mi
from
Leavenworth, KA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
St. John's Pediatrics
mi
from
Leavenworth, KA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Southeast Nebraska Cancer Center
mi
from
Lincoln, NE
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Southeast Nebraska Cancer Center
mi
from
Lincoln, NE
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Reno Oncology Associates
mi
from
Reno, NV
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Reno Oncology Associates
mi
from
Reno, NV
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Hematology-Oncology Associates of Northern NJ, PA Carol G. Simon Cancer Center
mi
from
Morristown, NJ
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Hematology-Oncology Associates of Northern NJ, PA Carol G. Simon Cancer Center
mi
from
Morristown, NJ
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Somerset Hematology Oncology Associates
mi
from
Somerville, NJ
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Somerset Hematology Oncology Associates
mi
from
Somerville, NJ
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Clinical Research Alliance, Inc.
mi
from
Lake Success, NY
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Clinical Research Alliance, Inc.
mi
from
Lake Success, NY
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Hematology Oncology Associates of Rockland
mi
from
Nyack, NY
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Hematology Oncology Associates of Rockland
mi
from
Nyack, NY
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Piedmont Hematology Oncology
mi
from
Winston-Salem, NC
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Piedmont Hematology Oncology
mi
from
Winston-Salem, NC
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Berks Hematology Oncology Associates
mi
from
W Reading, PA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Berks Hematology Oncology Associates
mi
from
W Reading, PA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Abington Hematology Oncology Associates
mi
from
Willow Grove, PA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Abington Hematology Oncology Associates
mi
from
Willow Grove, PA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
The West Clinic, PC
mi
from
Memphis, TN
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
The West Clinic, PC
mi
from
Memphis, TN